> Antigen, Antibodies, ELISA, Western Blot > Primary Antibody > Monoclonal Antibodies > KDR (VEGFR-2) AntibodyBrand |
Leading Biology | Catalog Number |
APR08086G |
Product Type |
Monoclonal Antibodies | Field of Research |
|
Product Overview |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality KDR (VEGFR-2) antibody.
|
||
Molecular Weight |
151527 Da
|
||
Cellular Localization |
Antigen Cellular Localization:
Cell junction. Endoplasmic reticulum. Note=Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). {ECO:0000250, ECO:0000269|PubMed:23529610} Isoform 2: Secreted.
|
||
Host |
Rabbit
|
||
Species Reactivity |
Human
|
||
Target |
A synthetic peptide corresponding to residues in extracellular domain of human KDR/VEGFR2 was used as an immunogen. It is predicted that this antibody does not cross react with other members of VEGF receptor family.
|
||
Clone |
EPRER16Y
|
||
Symbol |
FLK1, VEGFR2
|
||
GeneID |
|||
UniProt ID |
|||
Function |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
|
||
Summary |
The expression of VEGF and KDR correlates highly with the normal ocular vascularization in humans, but VEGF may also be necessary for nonvascular retinal developmental functions, especially for the coordination of neural retinal development and the preliminary steps of the establishment of the definitive stable retinal vasculature (1). KDR/flk-1 is one of two receptors for vascular endothelial growth factor, a potent angiogenic peptide. KDR/flk-1 is an early marker for endothelial cell progenitors, and its expression is restricted to endothelial cells in vivo (2). Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase KDR/Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1 have been studied to a limited extent. Activation of KDR/Flt1 by PGF resulted in intermolecular transphosphorylation of Flk1, thereby amplifying VEGF-driven angiogenesis through KDR/Flk1. Even though VEGF and PGF both bind KDR/Flt1, PGF uniquely stimulated the phosphorylation of specific KDR/Flt1 tyrosine residues and the expression of distinct downstream target genes (3).
|
||
Form |
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
||
Storage & Stability |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
Applications |
WB
|
||
Dilution |
WB~~1:500
|
||
Synonyms |
Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase insert domain receptor, KDR, Protein-tyrosine kinase receptor flk-1, CD309, KDR, FLK1, VEGFR2
|
||
Images |
|
||
Specification |
|||
Quantity |
|
||
| Select | Brand | Catalog No. | Product Name | Pack Size | Type | Field of Research | Specification | Quantity | Price(USD) | |
| 1 | Leading Biology | APG02467G | CCK4 / PTK7 Antibody (clone 4F9) | 50 μl | Monoclonal Antibodies |
|
$495.00 | Add Ask | ||
| 2 | Leading Biology | AMM04683G | GALT Antibody (clone 4C11) | 50 μg | Monoclonal Antibodies |
|
$545.00 | Add Ask | ||
| 3 | Leading Biology | AMM01402G | Vimentin (Mesenchymal Cell Marker) Antibody - With BSA and Azide | 50 ug | Monoclonal Antibodies |
|
$395.00 | Add Ask | ||
| 4 | Leading Biology | APR08280G | LTA4H / LTA4 Antibody (clone 9G8) | 50 μl | Monoclonal Antibodies |
|
$495.00 | Add Ask | ||
| 5 | Leading Biology | AMM00172G | CD1a / HTA1 (Mature Langerhans Cells Marker) Antibody - With BSA and Azide | 50 ug | Monoclonal Antibodies |
|
$395.00 | Add Ask | ||
| 6 | Leading Biology | AMM05750G | CEBPA Antibody | 100 μl | Monoclonal Antibodies |
|
$545.00 | Add Ask |
Leading Biology Inc.
2600 Hilltop DR, Building G, B Suite C138
Richmond, CA, 94806
Tel: 1-661-524(LBI)-0262
Email: info@leadingbiology.com
You have 0 item in your cart
You have 0 item in your inquiry list
